Prosecution Insights
Last updated: October 04, 2026
Application No. 18/649,671

Process for preparing an acetal from an olefin using an iodine-alkyl compound

Non-Final OA §112§DP
Filed
Apr 29, 2024
Priority
May 16, 2023 — EU 23173655.4
Examiner
MURESAN, ANA Z
Art Unit
Tech Center
Assignee
Evonik Oxeno GmbH & Co. Kg
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
548 granted / 731 resolved
+15.0% vs TC avg
Strong +31% interview lift
Without
With
+31.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
32 currently pending
Career history
752
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
41.3%
+1.3% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
27.8%
-12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 731 resolved cases

Office Action

§112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This Office action is responsive to Applicant's preliminary amendment filed April 29, 2024. As filed Claims 1-14 are pending. Priority This application filed 04/29/2024 claims foreign priority to EP23173655.4, filed 05/16/2023. Information Disclosure Statement Applicants' information disclosure statements (IDS) have been considered except where lined through. Please refer to Applicants' copy of the 1449 submitted herein. Claim Objection 1. Claim 1 is objected to because of the following informalities: claim 1 is objected to because of the following informalities: claim 1 should be amended to commence with article “A” and to recite “A process”. 2.Claims 2-14 are objected to because of the following informalities: claims 2-14 should be amended to commence with article “The” for proper antecedent basis to parent claim. 3. The recitation in claims 2-14 “Claim” should be replaces lower case. 4. Claims 1-2, 8-9, 12, 14 are objected for reciting improper Markush language: the recitation in claims “selected from” should be changed to “selected from the group consisting of”. See MPEP 803.02. “A Markush-type claim recites alternatives in a format such as "selected from the group consisting of A, B and C." Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The recitation in claim 1 “(CAS: 68478-92-2)” rendering said claim and its dependent ambiguous because is unclear if the limitations in the parenthesis is part of said claim. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 1.Claims 1-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 11773042. Although the claims at issue are not identical, they are not patentably distinct from each other because of the overlapping scope between the conflicting claims: both instant claims and the claims of the ‘042 patent are drawn to a process comprising the process steps of:initially charging an olefin; adding a compound of formula (1): PNG media_image1.png 200 400 media_image1.png Greyscale adding a Pt compound; adding an iodine-alkyl compound; adding an alcohol; feeding in CO and H2; heating the reaction mixture. 2.Claims 1-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 11912726. Although the claims at issue are not identical, they are not patentably distinct from each other because process comprising the process steps of: charging an olefin; adding a compound of formula (1); adding a Pt compound and a iodine compound; adding CO/H2 and heating the reaction mixture. 3.Claims 1-14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 of co-pending application SN 18345424. Although the claims at issue are not identical, they are not patentably distinct from each other because of the overlapping scope between the conflicting claims:they both are drawn to a process comprising treating an olefin; with compound of formula (1); adding a Pt compound and a iodine compound; adding CO/H2 and heating the reaction mixture. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. 1.Claims 1-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 11739042 (18064948). Although the claims at issue are not identical, they are not patentably distinct from each other because both insta claims and the claims of the ‘042 patent claim a process comprising the process steps of: charging an olefin; adding a compound of formula (1); adding a Pt compound and a iodine compound; adding CO/H2 and heating the reaction mixture. Conclusion Claims 1-14 are rejected. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANA MURESAN whose telephone number is (571)-270-7587. The examiner can normally be reached on Monday through Friday, 8:30 am to 5:30 pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANA Z MURESAN/Primary Examiner, Art Unit 1692
Read full office action

Prosecution Timeline

Apr 29, 2024
Application Filed
Sep 22, 2026
Non-Final Rejection mailed — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735444
CHEMICALLY CLEAVABLE GROUP
6y 0m to grant Granted Sep 15, 2026
Patent 12735378
PROCESS FOR PRODUCING PARA-EUGENOL AND/OR ORTHO-EUGENOL
3y 11m to grant Granted Sep 15, 2026
Patent 12729175
METHOD FOR PRODUCING COMPOSITION CONTAINING PURIFIED FLUORINE-CONTAINING ETHER COMPOUND
3y 4m to grant Granted Sep 08, 2026
Patent 12729212
METHOD FOR PRODUCING (2-METHYLPYRIMIDIN-5-YL)BORONIC ACID DERIVATIVE
3y 0m to grant Granted Sep 08, 2026
Patent 12723021
METHOD FOR PRODUCING TRISULFIDE COMPOUND OR SELENOTRISULFIDE COMPOUND
3y 11m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
99%
With Interview (+31.3%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 731 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month